Heartflow (HTFL) Asset Writedowns and Impairment (2024 - 2025)
Heartflow (HTFL) posted Asset Writedowns and Impairment of $359000.0 for Q4 2025, up 247.13% on a QoQ basis from -$244000.0 in Q4 2024, and up 247.13% year-over-year from $103419.1 in Q4 2024.
Powered by 
Analysis
Heartflow (HTFL) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Heartflow has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $359000.0 in Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment rose 247.13% year-over-year to $359000.0 in Q4 2025; TTM through Dec 2025 was $116000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $188000.0, up 177.05% from the prior year.
- Asset Writedowns and Impairment was $359000.0 for Q4 2025 at Heartflow, up from -$244000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $359000.0 in Q4 2025, with the low at -$244000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn |
| 10 | Prenetics Global | 357.49 Mn | 298.35 Mn | 30.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 359,000.00 |
| Dec 31, 2024 | -244,000.00 |
| Sep 30, 2024 | 1,000.00 |